Table 3.

ORs with 95% CIs for the association of between IM and HL overall and for EBV-positive and EBV-negative tumors in young adults and for all ages combined

Relative risk of HL after IM
IMYoung adults (18–44 yrs)All ages
HL overallEBV-positive HLEBV-negative HLHL overallEBV-positive HLEBV-negative HL
Ever versus never1.97 (1.29–3.01)3.96 (2.19–7.18)1.36 (0.81–2.26)1.84 (1.27–2.66)3.23 (1.89–5.55)1.35 (0.86–2.14)
Years since (versus never)
    1–43.26 (1.03–10.4)11.86 (3.10–45.3)0.41 (0.04–3.75)5.56 (1.73–17.9)11.42 (3.01–43.3)1.06 (0.18–6.20)
    5–93.93 (1.57–9.84)9.99 (3.27–30.5)2.31 (0.80–6.64)3.81 (1.56–9.32)8.85 (3.00–26.1)2.32 (0.81–6.62)
    10–140.93 (0.36–2.40)2.45 (0.72–8.29)0.67 (0.20–2.21)0.91 (0.35–2.33)2.31 (0.69–7.76)0.66 (0.20–2.18)
    15–191.32 (0.47–3.66)0.92 (0.11–7.90)1.46 (0.48–4.46)1.52 (0.57–4.03)0.84 (0.10–7.04)1.77 (0.62–5.07)
    ≥201.12 (0.41–3.00)1.30 (0.27–6.36)0.88 (0.24–3.26)0.80 (0.37–1.73)0.81 (0.18–3.53)0.63 (0.22–1.83)
Phomogeneity0.120.030.40<0.01<0.010.31
  • NOTE: Analyses are adjusted for matching variables (age, gender, and country) besides country-specific measures of maternal education. Tests for homogeneity between risk estimates, Phomogeneity, are adjusted for mononucleosis history.